Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MetroWilms
NCT05384821Phase 2Recruiting
- Sponsor
- Centre Oscar Lambret
- Start
- Sep 2022
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies, Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vincristine sulfate liposome injection, irinotecan, temozolomide, etoposide and isotretinoin in Wilms' tumor, sponsored by Centre Oscar Lambret. Primary endpoint: Disease control at 6 months. Started Sep 2022; status: recruiting.
02
Drugs
vincristine sulfate liposome injectionirinotecantemozolomideetoposideisotretinoin
03
Conditions
Wilms' tumor
Beyond the preview
Go deeper on NCT05384821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05384821.